Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1). Durvalumab is also known as a checkpoint inhibitor. This study is evaluating the combination regimen of mocetinostat and durvalumab in participants with Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer.
Checked against the public recordLast updated Apr 6, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Mirati Therapeutics Inc.
- Interventions being studied
- Drug: Mocetinostat - 50 mg; Drug: Mocetinostat - 70 mg; Drug: Mocetinostat - 90 mg; Drug: Mocetinostat - Recommended Phase 2 Dose (70 mg); Drug: Durvalumab - 1500 mg
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Phase 1-Diagnosis of advanced or metastatic solid tumor; Phase 2-Diagnosis of NSCLC * Not amenable to treatment with curative intent * Adequate bone marrow and organ function Exclusion Criteria: * Impaired heart function * Uncontrolled tumor in the brain * Other active cancer
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Southern Cancer Center, PCMobile, Alabama
- David Geffen School of Medicine at UCLALos Angeles, California
- Woodlands Medical Specialists - PensacolaPensacola, Florida
- Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityChicago, Illinois
- NorthShore University Health SystemEvanston, Illinois
- Unniversity of Minnesota Masonic Cancer CenterMinneapolis, Minnesota
- Hackensack University Medical CenterHackensack, New Jersey
- Montefiore Medical CenterThe Bronx, New York
- Sarah Cannon Research InstituteNashville, Tennessee
- Mary Crowley Cancer Research CentersDallas, Texas
- Texas Oncology - Denton SouthDenton, Texas
- Texas Oncology-Plano WestPlano, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 6, 2021. Always confirm current availability with the study team.